Cleary Gottlieb represented Monograph Capital in a PIPE investment in UroGen Pharma Ltd. (UroGen), a biotech company headquartered in Princeton, New Jersey, with operations in Israel.
UroGen intends to use the net investment proceeds for non-clinical and clinical development activities for its product candidates, commercialization expense, and general corporate purposes.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, and hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.
Monograph Capital is a life sciences venture firm that partners with young companies and entrepreneurs to support breakthrough therapeutics, diagnostics, and digitally enabled health care to improve the practice of medicine.
For more information, please see the press release here.